b7h3/cd3-targeting t-cell engaging molecule tak-280 vs trodelvy
| b7h3/cd3-targeting t-cell engaging molecule tak-280 | trodelvy | |
|---|---|---|
| Developers | 0 | 0 |
| Clinical trials | 0 | 0 |
| FDA decisions | 0 | 0 |
| Generic name | B7H3/CD3-targeting T-cell Engaging Molecule TAK-280 | sacituzumab |